Literature DB >> 8876957

Synovial fluid cell analysis.

M Dougados1.   

Abstract

Arthrocentesis has to be considered as a part of the clinical examination. A reasonable amount of aspirated synovial fluid is the best argument in favour of an objective articular disorder. Moreover some very simple evaluations are very helpful to make a diagnosis and to distinguish some particularities of rheumatic diseases. Such evaluations have to include both bacterial and synovial fluid analysis. Moreover, when performing synovial fluid analysis, a search for microcrystals is also performed. Haemarthrosis can easily be distinguished from a traumatic tap if the investigator is observing carefully the synovial fluid entering in the syringe. The diseases responsible for haemarthrosis differ with the age of patients: chondrocalcinosis, together with osteoarthrosis, is the most frequent aetiology in the elderly; disorders of haemostasis and synovial tumours are mostly observed in children and young adults. Paucicellular (< 1000 cells/mm3) synovial fluid is observed in different 'mechanical' disorders. In the case of purulent synovial fluid the primary diagnosis is septic arthritis. However, the most common aetiology is probably crystal-induced acute arthritis. Differential cell count analysis performed in case of 'inflammatory' (> 1000 or 2000 cells/mm3) synovial fluid usually shows a predominance of polymorphonuclear cells. However, high cellularity may sometimes be associated with a predominance of other cells, i.e. lymphocytes, monocytes, eosinophils. In this situation, such a simple evaluation (differential cell count analysis) is very helpful in making a diagnosis, e.g. eosinophilic arthritis, or to distinguish some particularities of rheumatic diseases, e.g. absence of cartilage breakdown in case of lymphocytic arthritis.

Entities:  

Mesh:

Year:  1996        PMID: 8876957     DOI: 10.1016/s0950-3579(96)80047-1

Source DB:  PubMed          Journal:  Baillieres Clin Rheumatol        ISSN: 0950-3579


  7 in total

Review 1.  The role of synovitis in pathophysiology and clinical symptoms of osteoarthritis.

Authors:  Jérémie Sellam; Francis Berenbaum
Journal:  Nat Rev Rheumatol       Date:  2010-10-05       Impact factor: 20.543

2.  Rheumatoid Arthritis Morning Stiffness Is Associated With Synovial Fibrin and Neutrophils.

Authors:  Dana E Orange; Nathalie E Blachere; Edward F DiCarlo; Serene Mirza; Tania Pannellini; Caroline S Jiang; Mayu O Frank; Salina Parveen; Mark P Figgie; Ellen M Gravallese; Vivian P Bykerk; Ana-Maria Orbai; Sarah L Mackie; Susan M Goodman
Journal:  Arthritis Rheumatol       Date:  2020-02-12       Impact factor: 10.995

3.  [Rheumatoid arthritis combined with pigmented villonodular synovitis: A case report and literature review].

Authors:  J J Peng; T Liu
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-12-18

4.  Presence of MRI-detected joint effusion and synovitis increases the risk of cartilage loss in knees without osteoarthritis at 30-month follow-up: the MOST study.

Authors:  Frank W Roemer; Ali Guermazi; David T Felson; Jingbo Niu; Michael C Nevitt; Michel D Crema; John A Lynch; Cora E Lewis; James Torner; Yuqing Zhang
Journal:  Ann Rheum Dis       Date:  2011-07-25       Impact factor: 19.103

Review 5.  Platelet-rich plasma for managing pain and inflammation in osteoarthritis.

Authors:  Isabel Andia; Nicola Maffulli
Journal:  Nat Rev Rheumatol       Date:  2013-10-01       Impact factor: 20.543

6.  Changes in Hematobiochemical, Radiological, and Synovial Fluid Parameter in Patients of Osteoarthritis Knee with Effusion: A Prospective Observational Study.

Authors:  Sachin Jain; Sameer Gupta; Tarun Naugraiya
Journal:  J Orthop Case Rep       Date:  2021-08

Review 7.  Laboratory testing of extravascular body fluids: National recommendations on behalf of the Croatian Society of Medical Biochemistry and Laboratory Medicine. Part II - Synovial fluid.

Authors:  Anja Jokic; Lara Milevoj Kopcinovic; Jelena Culej; Irena Kocijan; Marija Bozovic
Journal:  Biochem Med (Zagreb)       Date:  2020-08-05       Impact factor: 2.313

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.